Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BioNTech

BioNTech, Medigene Ink Immunotherapy Pact Against Cancer

BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer.

Benzinga

Pfizer/BioNTech's Omicron-Targeted COVID-19 To Miss March Timeline: Reuters

Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) omicron-targeted COVID-19 vaccine is delayed by several weeks due to a slower-than-expected data gathering process,

Benzinga

This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart

Macy's Inc (NYSE: M) retail stores have something for everyone in the family, and over the past year, has returned unmistakable gains for bullish traders and investors.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

BioNTech Unveils First Modular mRNA Manufacturing Facility In Africa

BioNTech SE (NASDAQ: BNTX), which developed the first widely approved COVID-19 shot together with Pfizer Inc (NYSE: PFE),

Benzinga

BioNTech Pledges African Access to its Future Cancer Drugs

Germany's BioNTech, which is preparing to produce its COVID-19 vaccine or other disease-preventing shots in Africa, said that novel cancer therapies it is working on will in future be available on the continent at affordable prices. "We pledge as BioNTech to develop our cancer medicines also according to the needs…

Asharq Al-Awsat

BioNTech plans modular vaccine factories in Africa

German vaccine maker BioNTech unveiled plans Wednesday to establish manufacturing facilities in Africa that would boost the availability of much-needed medicines on the continent

The Independent UK

Why BioNTech Shares Are Falling Today

BioNTech SE (NASDAQ: BNTX) is trading lower Monday morning after the U.S. Food and Drug Administration (FDA) requested additional data before approving its COVID-19 vaccine for children aged six months to four years old.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

US drug regulator postpones meeting on infant Covid vaccines

Washington (AFP) - The US Food and Drug Administration (FDA) on Friday announced it was postponing a meeting scheduled for next week where a panel of experts would have decided whether to endorse the Pfizer-BioNTech Covid vaccine for infants.

AFP

Pfizer accused of pandemic profiteering as profits double

Drugmaker makes $37bn in vaccine sales and predicts bumper year ahead from Covid jabs and pill

The Guardian - UK

Pfizer Seeks US Approval of Covid Vaccine for Children under 5

Pfizer and BioNTech said Tuesday they are seeking emergency authorization from US health regulators for use of their Covid vaccine for children aged over six months and under five years. If the Food and Drug Administration (FDA) authorizes the two-shot regimen, it will become the first Covid vaccine available to…

Asharq Al-Awsat

Covid news: Anger as Tory MP says lockdown breach ‘like parking fine’; Germany could relax restrictions in March – as it happened

Pfizer-BioNTech seeks US approval for under-5s Covid inoculation; Lithuania to scrap Covid pass on Saturday

The Guardian - AU

Pfizer seeks US approval of Covid vaccine for children under 5

Washington (AFP) - Pfizer and BioNTech said Tuesday they are seeking emergency authorization from US health regulators for use of their Covid vaccine for children aged over six months and under five years.

AFP

Pfizer Could Seek COVID-19 Vaccine Emergency Approval For Children Under 5 This Week

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) are likely to submit a request for an emergency use authorization to the U.S.

Benzinga

Down Close to 40% Year-To-Date, Now is a Good Time to Scoop Up Moderna and BioNTech

The ongoing market correction has caused the shares of popular vaccine makers Moderna (MRNA) and BioNTech (BNTX) to decline nearly 40% in price so far this year. However, because the demand for COVID-19 vaccines remains strong globally, these companies are expected to generate substantial revenues and profits in the coming…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

What Are Whales Doing With BioNTech

Someone with a lot of money to spend has taken a bearish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

ABC News

Anthony Fauci says Omicron-specific COVID-19 vaccine may be prudent but not needed, as clinical trials announced

A COVID-19 vaccine specifically targeting the Omicron variant would be "prudent", even if it ultimately may not be needed, the top US infectious disease official says, as Pfizer announces trials for such a vaccine.

Evening Standard

Pfizer and BioNTech launch clinical trial for Omicron-specific vaccine

Pfizer Inc and BioNTech have announced the start a clinical trial to test a new version of their vaccine specifically designed to target the Omicron variant of Covid-19 Omicron variant.

Tribune News Service

Pfizer, BioNTech begin study of omicron-specific COVID vaccine

Pfizer Inc. said it is starting a study of a COVID-19 vaccine that targets the omicron variant, exploring its use in previously vaccinated younger and middle-aged adults as well as those who haven’t received another coronavirus shot.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Pfizer, BioNTech Launch Omicron-Targeted COVID-19 Vaccine Trial

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have

Asharq Al-Awsat

Pfizer and BioNTech Launch Trial of Omicron-Targeted COVID Vaccine

Pfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. The companies plan to test the immune…

Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

AFP

Pfizer-BioNTech begin Omicron vaccine trial

Washington (AFP) - Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday.

The Guardian - UK

Pfizer launches Omicron vaccine trial; UK reports highest daily deaths since February – as it happened

Company hopes vaccine will be ready for approval by March; UK reports 439 deaths and more than nearly 95,000 cases

Benzinga

A Bearish Sign Appears On BioNTech's Chart

If history is any guide, there may be trouble ahead for shares of BioNTech (NASDAQ:BNTX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Investors Business Daily

Pfizer Trends Sideways, But A Looming Catalyst Could Arrive Next Month

White House advisor Anthony Fauci said U.S. officials could authorize Pfizer and BioNTech's Covid vaccine for children younger than 5 next month.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

International Monetary Fund

1,964 stories

Office for National Statistics

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.